MAPT and Alzheimer disease: For example, 2-methyl-5-(3-4-[(S)-methylsulfinyl]phenyl-1-benzofuran-5-yl)-1,3,4-oxadiazole (MMBO) and NP12 have been reported to decrease tau phosphorylation and reverse cognitive deficits in AD mouse models, which are novel GSK-3 inhibitors [17, 18].